Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash from Operations (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Cash from Operations for 4 consecutive years, with 6456000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 68.78% to 6456000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 33327000.0, a 40.45% increase, with the full-year FY2025 number at 33327000.0, up 40.45% from a year prior.
  • Cash from Operations was 6456000.0 for Q4 2025 at Spruce Biosciences, up from 48471000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 12700000.0 in Q1 2025 to a low of 48471000.0 in Q3 2025.
  • A 4-year average of 10265562.5 and a median of 11157500.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 657.25% in 2024, then soared 184.9% in 2025.
  • Spruce Biosciences' Cash from Operations stood at 11738000.0 in 2022, then grew by 4.51% to 11209000.0 in 2023, then plummeted by 84.47% to 20677000.0 in 2024, then surged by 68.78% to 6456000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Cash from Operations are 6456000.0 (Q4 2025), 48471000.0 (Q3 2025), and 8900000.0 (Q2 2025).